Skip to main content
SpringerLink
Log in

The incidence of cardiac events “seems to be higher than previously reported” for patients receiving trastuzumab and docetaxel

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Jacquemin L, Duck L, Berliere M, Machiels JP, Mazzeo F, Whenham N, Hammouch F, Baurain JF.Retrospective analysis of cardiac safety in EBC women treated with the chemotherapy regimen: FEC followed by docetaxel+trastuzumab. 7th European Breast Cancer Conference: abstr. 49, 24 Mar 2010. Available from: URL: http://www.ecco-org.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The incidence of cardiac events “seems to be higher than previously reported” for patients receiving trastuzumab and docetaxel. React. Wkly. 1300, 2 (2010). https://doi.org/10.2165/00128415-201013000-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013000-00004

Keywords

Search

Navigation